Abstract
We have shown that ER-negative and invasive human breast cancer cell lines MDA-MB-468 and MDA-MB-231 have constitutively higher mitogen activated protein kinase (ERK1&2/MAPK) when compared to the ER-positive and non-invasive MCF-7 human breast cancer cells. In MCF-7 cells, TGFα stimulation induced only transient MAPK activation, leading to a transient increase in cell migration. However, MDA 231 and MDA 468 cells, TGFα stimulation induced sustained MAPK activation, which correlated with enhanced cell motility and in vitro invasion. Serum stimulation activates ERK/MAPK activity persistently in both ER-positive and ER-negative breast cancer cells, leading to enhanced and sustained cell migration. Inhibition of MAPK activation by anti-sense MEK expression in MDA-MB-468 cells significantly inhibits cell migration and in vitro invasion. In contrast, MCF-7 cells expressing constitutively activated MEK show a significant increase in MAPK activity and cell migration, but this failed to enhance in vitro invasion. The kinetic profiles of MAPK activation and inhibition show a relationship between the duration and magnitude of MAPK activation and cell migration in both ER-positive and ER-negative human breast cancer cells. These studies show that cell motility is modulated by the magnitude and the duration of MAPK activation; but increased activation of MAPK may not be sufficient to allow in vitro invasion in non-invasive MCF-7 breast cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chen P, Xie H, Wells A . 1996 Mol. Biol. Cell 7: 871–881
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159
Cobb MH, Goldsmith EJ . 1995 J. Biol. Chem. 270: 14843–14846
Cowley S, Paterson H, Kemp P, Marshall CJ . 1994 Cell 77: 841–852
Doerr ME, Jones JI . 1996 J. Biol. Chem. 271: 2443–2447
Fan WH, Lu YL, Deng F, Ge XM, Liu S, Tang PH . 1998 Cell Res. 8: 63–71
Friedl P, Noble PB, Walton PA, Laird DW, Chauvin PJ, Tabah RJ, Black M, Zanker KS . 1995 Cancer Res. 55: 4557–4560
Gilhooly EM, Rose DP . 1999 Int. J. Oncol. 15: 267–270
Gopalakrishna R, Gundimeda U, Fontana JA, Clarke R . 1999 Cancer Lett. 136: 143–151
Gotoh I, Fukuda M, Adachi M, Nishida E . 1999 J. Biol. Chem. 274: 11874–11880
Hartmann G, Weidner KM, Schwarz H, Birchmeier W . 1994 J. Biol. Chem. 269: 21936–21939
Heldin CH, Ostman A . 1996 Cytokine Growth Factor Rev. 7: 3–10
Hunter T . 1995 Cell 80: 225–236
Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA . 1997 J. Cell. Biol. 137: 481–492
Kondapaka SB, Fridman R, Reddy KB . 1997 Int. J. Cancer 70: 722–726
Lewis TS, Shapiro PS, Ahn NG . 1998 Adv. Cancer Res. 74: 49–139
Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR . 1998 Am. J. Pathol. 153: 1411–1423
Manske M, Bade EG . 1994 Int. Rev. Cytol. 155: 49–96
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG . 1994 Science 265: 966–970
Marshall CJ . 1994 Curr. Opin. Genet. Dev. 4: 82–89
McCawley LJ, Li S, Wattenberg EV, Hudson LG . 1999 J. Biol. Chem. 274: 4347–4353
Mishra S, Hamburger AW . 1993 Biochem. Biophys. Res. Commun. 191: 1066–1072
Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, Weber MJ, Gonias SL . 1999 J. Cell. Biol. 146: 149–164
Nishida E, Gotoh Y . 1993 Trends Biochem. Sci. 18: 128–131
Potempa S, Ridley AJ . 1998 Mol. Biol. Cell. 9: 2185–2200
Prasad KS, Brandt SJ . 1997 J. Biol. Chem. 272: 11457–11462
Price JT, Wilson HM, Haites NE . 1996 Eur. J. Cancer 32A: 1977–1982
Rajkumar T, Gullick WJ . 1994 Breast Cancer Res. Treat. 29: 3–9
Reddy KB, Keshamouni VG, Chen YQ . 1999a Int. J. Onco. 15: 301–306
Reddy KB, Krueger JS, Kondapaka SB, Diglio CA . 1999b Int. J. Cancer 82: 268–273
Rigot V, Lehmann M, Andre F, Daemi N, Marvaldi J, Luis J . 1998 J. Cell. Sci. 111: 3119–3127
Sato C, Tsuboi R, Shi CM, Rubin JS, Ogawa H . 1995 J. Invest. Dermatol. 104: 958–963
Seger R, Biener Y, Feinstein R, Hanoch T, Gazit A, Zick Y . 1995 J. Biol. Chem. 270: 28325–28330
Shao ZM, Wu J, Shen ZZ, Barsky SH . 1998 Anticancer Res. 18: 1435–1439
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC . 1997 J. Clin. Invest. 99: 1478–1483
Slack JK, Catling AD, Eblen ST, Weber MJ, Parsons JT . 1999 J. Biol. Chem. 274: 27177–27184
Traverse S, Seedorf K, Paterson H, Marshall CJ, Cohen P, Ullrich A . 1994 Curr. Biol. 4: 694–701
Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K . 1994 Nature 367: 651–654
Xie H, Pallero MA, Gupta K, Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenburger DA, Murphy-Ullrich JE, Wells A . 1998 J. Cell. Sci. 111: 615–624
Zeigler ME, Chi Y, Schmidt T, Varani J . 1999 J. Cell. Physiol. 180: 271–284
Zheng CF, Guan KL . 1994 J. Biol. Chem. 269: 19947–19952
Acknowledgements
This work was supported in part by NIH Grant CA 64248 (to KB Reddy) and CA 83964 (to KB Reddy).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krueger, J., Keshamouni, V., Atanaskova, N. et al. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20, 4209–4218 (2001). https://doi.org/10.1038/sj.onc.1204541
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204541
Keywords
This article is cited by
-
Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line
Scientific Reports (2022)
-
Genome-wide CRISPR screen for HSV-1 host factors reveals PAPSS1 contributes to heparan sulfate synthesis
Communications Biology (2022)
-
Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor
Cellular Oncology (2022)
-
Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM
British Journal of Cancer (2021)
-
Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells
Oncogene (2017)